BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A gatekeeper point mutation, involving the substitution of threonine with isoleucine at position 315 (T315I) in the BCR–ABL protein, was identified in CML patients resistant to imatinib in 2001.52